Investigation into XOMA Royalty Acquisition
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Should l Buy LGND?
Source: PRnewswire
- Investigation Launched: Rowley Law PLLC is investigating potential securities law violations by XOMA Royalty Corporation and its board regarding the acquisition proposal by Ligand Pharmaceuticals, indicating significant concerns over transaction compliance.
- Transaction Details Revealed: The acquisition is valued at approximately $739 million, with shareholders set to receive $39.00 per share plus a contingent value right, reflecting the market's potential reaction and the protection of shareholder interests.
- Expected Completion Timeline: The transaction is anticipated to close in the third quarter of 2026, with the clarity of the timeline potentially influencing shareholder confidence and subsequent decision-making.
- Legal Support Information: Rowley Law PLLC has provided contact details for shareholders seeking more information about the investigation, demonstrating the firm's commitment to offering legal support and enhancing representation in complex corporate litigation.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy LGND?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on LGND
Wall Street analysts forecast LGND stock price to rise
6 Analyst Rating
6 Buy
0 Hold
0 Sell
Strong Buy
Current: 231.270
Low
220.00
Averages
237.20
High
270.00
Current: 231.270
Low
220.00
Averages
237.20
High
270.00
About LGND
Ligand Pharmaceuticals Incorporated is a biopharmaceutical company enabling scientific advancement through supporting the clinical development of medicines. It does this by financing, licensing its technologies or both. It operates two infrastructure-light royalty-generating IP platform technologies. Its Captisol platform technology is a chemically modified cyclodextrin with a structure designed to optimize the solubility and stability of drugs. This technology has enabled FDA-approved products, including Gilead’s Veklury, Amgen’s Kyprolis, Baxter’s Nexterone, and Acrotech Biopharma’s Evomela. Its NITRICIL platform technology facilitates tunable dosing, permitting an adjustable drug release profile to allow proprietary formulations that target a range of indications. Its technologies also include HepDirect, LTP and BEPro Technology Platform, and Pelican Expression Technology. It has multiple alliances, licenses and other business relationships with various pharmaceutical companies.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Ligand Pharmaceuticals to Acquire XOMA Royalty for $739 Million
- Transaction Overview: Ligand Pharmaceuticals has agreed to acquire XOMA Royalty Corporation for $39.00 per share in cash, valuing the transaction at approximately $739 million, which significantly expands Ligand's royalty portfolio and solidifies its position as a leading biopharma royalty aggregator.
- Asset Portfolio Expansion: The acquisition adds over 120 commercial, clinical, and preclinical assets to Ligand's portfolio, including seven marketed products, with key commercial programs such as Roche's VABYSMO, Day One Pharmaceuticals' OJEMDA, and Zevra Therapeutics' MIPLYFFA, which are expected to drive future revenue growth for the company.
- Earnings Outlook Improvement: Ligand anticipates that the acquisition will be immediately accretive to adjusted earnings per share (EPS) and has raised its 2026 adjusted EPS guidance to $8.50-$9.50, compared to $8.13 for full year 2025, projecting the deal will add $1.50 per share to adjusted EPS in 2027.
- Strategic Importance: Ligand emphasized that the combined portfolio enhances its ability to support broader patient access and advance late-stage assets from Takeda's externalized portfolio, including mezagitamab, osavampator, volixibat, and OHB-607.
See More
Investigation into XOMA Royalty Acquisition
- Investigation Launched: Rowley Law PLLC is investigating potential securities law violations by XOMA Royalty Corporation and its board regarding the acquisition proposal by Ligand Pharmaceuticals, indicating significant concerns over transaction compliance.
- Transaction Details Revealed: The acquisition is valued at approximately $739 million, with shareholders set to receive $39.00 per share plus a contingent value right, reflecting the market's potential reaction and the protection of shareholder interests.
- Expected Completion Timeline: The transaction is anticipated to close in the third quarter of 2026, with the clarity of the timeline potentially influencing shareholder confidence and subsequent decision-making.
- Legal Support Information: Rowley Law PLLC has provided contact details for shareholders seeking more information about the investigation, demonstrating the firm's commitment to offering legal support and enhancing representation in complex corporate litigation.
See More
Investigation Alerts for Multiple Mergers
- XOMA Acquisition Deal: XOMA Royalty Corporation is set to be acquired by Ligand Pharmaceuticals for $39.00 per share, totaling approximately $739 million; however, this price is below its 52-week high of $42.38, raising concerns among shareholders about the fairness of the transaction.
- Organon Merger Case: Organon & Co. will be acquired by Sun Pharmaceutical for $14.00 per share in cash, with an enterprise valuation of $11.75 billion, and the investigation focuses on whether the Organon Board failed to treat shareholders fairly, potentially impacting shareholder rights.
- RE/MAX Acquisition Proposal: RE/MAX Holdings, Inc. will be acquired by The Real Brokerage, allowing shareholders to choose between 5.152 shares of the new company or $13.80 in cash per share, with investigations into whether the Board failed to handle the transaction fairly, affecting shareholder interests.
- Soleno Acquisition Investigation: Soleno Therapeutics, Inc. will be acquired by Neurocrine Biosciences for $53.00 per share, representing a total transaction value of approximately $2.9 billion, but this price is below its 52-week high of $90.32, raising questions about the Board's fairness in the deal.
See More
Ligand Pharmaceuticals to Acquire XOMA Royalty for $739 Million
- Acquisition Details: Ligand Pharmaceuticals has agreed to acquire XOMA Royalty for $39.00 per share in cash, totaling approximately $739 million, with unanimous board approval and expected closure in Q3 2026, indicating strong confidence in future growth.
- Financial Guidance Increase: The transaction is expected to be immediately accretive to Ligand's earnings per share, raising the 2026 revenue guidance to $270 million-$310 million and adjusted EPS guidance from $8.00-$9.00 to $8.50-$9.50, reflecting positive expectations from the acquisition.
- Portfolio Expansion: The acquisition will add over 120 commercial, clinical, and preclinical assets to Ligand's royalty portfolio, raising the royalty revenue outlook from $200 million-$225 million to $225 million-$250 million, further enhancing the company's competitive position in the market.
- Strategic Growth Opportunity: CEO Todd Davis stated that this acquisition will significantly strengthen and diversify the company's portfolio, adding seven marketed products and nearly doubling the Phase 2 and 3 assets, which is expected to create substantial value for shareholders.
See More
Ligand Pharmaceuticals to Acquire XOMA for $740M in Cash
- Acquisition Deal Size: Ligand Pharmaceuticals has reached a $740 million all-cash deal to acquire XOMA at $39 per share, with an announcement expected as soon as Monday, significantly enhancing Ligand's market position.
- Market Valuation Analysis: According to FactSet, XOMA had a market value of approximately $450 million as of last Friday, or nearly $700 million on a fully diluted basis, and this acquisition will enrich Ligand's portfolio with over 200 drugs and experimental treatments.
- Stock Price Reaction: Following the acquisition news, XOMA shares rose 2.9% in premarket trading to $39, indicating a positive market response and potentially reflecting investor confidence in Ligand's future growth prospects.
- Strategic Implications: This acquisition allows Ligand to not only expand its product line but also to further solidify its competitive advantage in the pharmaceutical industry, particularly in high-growth areas, which is expected to provide strong support for future revenue growth.
See More
FDA Approves Filspari for Rare Kidney Disorder Treatment
- FDA Approval: The U.S. FDA approved Filspari on Monday for treating focal segmental glomerulosclerosis (FSGS), making it the only approved treatment for this condition, potentially benefiting over 30,000 patients in the U.S. and significantly improving their quality of life.
- Clinical Trial Results: Filspari demonstrated a 48% reduction in proteinuria over 108 weeks in late-stage trials, validating its efficacy, and the FDA's approval strongly supports Travere Therapeutics' market outlook.
- Analyst Optimism: Canaccord raised its price target for Filspari from $47 to $56, projecting peak sales of $547 million by 2032, indicating strong market confidence in the drug's potential.
- Positive Market Reaction: Shares of Travere Therapeutics surged over 40% in pre-market trading on Tuesday following the FDA approval, reflecting enthusiastic investor sentiment, although the stock has still declined about 21% year-to-date.
See More
Ligand Pharmaceuticals to Acquire XOMA Royalty for $739 Million
- Transaction Overview: Ligand Pharmaceuticals has agreed to acquire XOMA Royalty Corporation for $39.00 per share in cash, valuing the transaction at approximately $739 million, which significantly expands Ligand's royalty portfolio and solidifies its position as a leading biopharma royalty aggregator.
- Asset Portfolio Expansion: The acquisition adds over 120 commercial, clinical, and preclinical assets to Ligand's portfolio, including seven marketed products, with key commercial programs such as Roche's VABYSMO, Day One Pharmaceuticals' OJEMDA, and Zevra Therapeutics' MIPLYFFA, which are expected to drive future revenue growth for the company.
- Earnings Outlook Improvement: Ligand anticipates that the acquisition will be immediately accretive to adjusted earnings per share (EPS) and has raised its 2026 adjusted EPS guidance to $8.50-$9.50, compared to $8.13 for full year 2025, projecting the deal will add $1.50 per share to adjusted EPS in 2027.
- Strategic Importance: Ligand emphasized that the combined portfolio enhances its ability to support broader patient access and advance late-stage assets from Takeda's externalized portfolio, including mezagitamab, osavampator, volixibat, and OHB-607.
See More
Investigation into XOMA Royalty Acquisition
- Investigation Launched: Rowley Law PLLC is investigating potential securities law violations by XOMA Royalty Corporation and its board regarding the acquisition proposal by Ligand Pharmaceuticals, indicating significant concerns over transaction compliance.
- Transaction Details Revealed: The acquisition is valued at approximately $739 million, with shareholders set to receive $39.00 per share plus a contingent value right, reflecting the market's potential reaction and the protection of shareholder interests.
- Expected Completion Timeline: The transaction is anticipated to close in the third quarter of 2026, with the clarity of the timeline potentially influencing shareholder confidence and subsequent decision-making.
- Legal Support Information: Rowley Law PLLC has provided contact details for shareholders seeking more information about the investigation, demonstrating the firm's commitment to offering legal support and enhancing representation in complex corporate litigation.
See More
Investigation Alerts for Multiple Mergers
- XOMA Acquisition Deal: XOMA Royalty Corporation is set to be acquired by Ligand Pharmaceuticals for $39.00 per share, totaling approximately $739 million; however, this price is below its 52-week high of $42.38, raising concerns among shareholders about the fairness of the transaction.
- Organon Merger Case: Organon & Co. will be acquired by Sun Pharmaceutical for $14.00 per share in cash, with an enterprise valuation of $11.75 billion, and the investigation focuses on whether the Organon Board failed to treat shareholders fairly, potentially impacting shareholder rights.
- RE/MAX Acquisition Proposal: RE/MAX Holdings, Inc. will be acquired by The Real Brokerage, allowing shareholders to choose between 5.152 shares of the new company or $13.80 in cash per share, with investigations into whether the Board failed to handle the transaction fairly, affecting shareholder interests.
- Soleno Acquisition Investigation: Soleno Therapeutics, Inc. will be acquired by Neurocrine Biosciences for $53.00 per share, representing a total transaction value of approximately $2.9 billion, but this price is below its 52-week high of $90.32, raising questions about the Board's fairness in the deal.
See More
Ligand Pharmaceuticals to Acquire XOMA Royalty for $739 Million
- Acquisition Details: Ligand Pharmaceuticals has agreed to acquire XOMA Royalty for $39.00 per share in cash, totaling approximately $739 million, with unanimous board approval and expected closure in Q3 2026, indicating strong confidence in future growth.
- Financial Guidance Increase: The transaction is expected to be immediately accretive to Ligand's earnings per share, raising the 2026 revenue guidance to $270 million-$310 million and adjusted EPS guidance from $8.00-$9.00 to $8.50-$9.50, reflecting positive expectations from the acquisition.
- Portfolio Expansion: The acquisition will add over 120 commercial, clinical, and preclinical assets to Ligand's royalty portfolio, raising the royalty revenue outlook from $200 million-$225 million to $225 million-$250 million, further enhancing the company's competitive position in the market.
- Strategic Growth Opportunity: CEO Todd Davis stated that this acquisition will significantly strengthen and diversify the company's portfolio, adding seven marketed products and nearly doubling the Phase 2 and 3 assets, which is expected to create substantial value for shareholders.
See More
Ligand Pharmaceuticals to Acquire XOMA for $740M in Cash
- Acquisition Deal Size: Ligand Pharmaceuticals has reached a $740 million all-cash deal to acquire XOMA at $39 per share, with an announcement expected as soon as Monday, significantly enhancing Ligand's market position.
- Market Valuation Analysis: According to FactSet, XOMA had a market value of approximately $450 million as of last Friday, or nearly $700 million on a fully diluted basis, and this acquisition will enrich Ligand's portfolio with over 200 drugs and experimental treatments.
- Stock Price Reaction: Following the acquisition news, XOMA shares rose 2.9% in premarket trading to $39, indicating a positive market response and potentially reflecting investor confidence in Ligand's future growth prospects.
- Strategic Implications: This acquisition allows Ligand to not only expand its product line but also to further solidify its competitive advantage in the pharmaceutical industry, particularly in high-growth areas, which is expected to provide strong support for future revenue growth.
See More
FDA Approves Filspari for Rare Kidney Disorder Treatment
- FDA Approval: The U.S. FDA approved Filspari on Monday for treating focal segmental glomerulosclerosis (FSGS), making it the only approved treatment for this condition, potentially benefiting over 30,000 patients in the U.S. and significantly improving their quality of life.
- Clinical Trial Results: Filspari demonstrated a 48% reduction in proteinuria over 108 weeks in late-stage trials, validating its efficacy, and the FDA's approval strongly supports Travere Therapeutics' market outlook.
- Analyst Optimism: Canaccord raised its price target for Filspari from $47 to $56, projecting peak sales of $547 million by 2032, indicating strong market confidence in the drug's potential.
- Positive Market Reaction: Shares of Travere Therapeutics surged over 40% in pre-market trading on Tuesday following the FDA approval, reflecting enthusiastic investor sentiment, although the stock has still declined about 21% year-to-date.
See More
